ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

IGF2BP3-induced activation of EIF5B contributes to progression ofhepatocellular carcinoma cells br

LI, Xiaoyin; Wang, Qian; Liang, Hongfeng; Chen, Shisheng; Chen, Haiwen; Lu, Yaoyong*; Yang, Changfu*广东省人民医院; 广州中医药大学; 南方医科大学
Oncology Research2022DOI: 10.32604/or.2022.026511
6阅读
引用收藏
分享

摘要

In this study, we investigated the functional role of eukaryotic initiation factor 5B (EIF5B) in hepatocellularcarcinoma (HCC) and the underlying mechanisms. Bioinformatics analysis demonstrated that the EIF5B transcriptand protein levels as well as the EIF5Bcopy number were significantly higher in the HCC tissues compared with thenon-cancerous liver tissues. Down-regulation of EIF5B significantly decreased proliferation and invasiveness of theHCC cells. Furthermore, EIF5B knockdown suppressed epithelial-mesenchymal transition (EMT) and the cancer stemcell (CSC) phenotype. Down-regulation of EIF5B also increased the sensitivity of HCC cells to 5-fluorouracil (5-FU).In the HCC cells, activation of the NF-kappa B signaling pathway and IkB phosphorylation was significantly reducedby EIF5B silencing. IGF2BP3 increased the stability of the EIF5B mRNA in an m6A-dependent manner. Our datasuggested that EIF5B is a promising prognostic biomarker and therapeutic target in HCC

学科与关键词

关键词
EIF5BNF-jBEpithelial-mesenchymal transitionCancer stem cellsN6-methyladenosineHepatocellular carcinoma
相关
加载中…
  • EIF5A expression and its role as a potential diagnostic biomarker in hepatocellular carcinoma
    Li, Linjing*; Li, Xin; Zhang, Qingyan; Ye, Tao; Zou, Shuli; Yan, JingAmerican Journal of Cancer Research, 2021, 12(16): 4774-4779.被引 5
  • eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway
    Sun, Liping; Liu, Shuguang; Wang, Xiaopai; Zheng, Xuefeng; Chen, Ya; Shen, Hong*Journal of Translational Medicine, 2021, 19(1): 216.被引 16
  • IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression
    Long Jun; Guo Hongyan; Cui Shichang; Zhang Haiyan; Liu Xinmin; Li Danning; Han Zimeng; Xi Linfeng; Kou Wenyi; Xu Jiangnan; Li Tao Sheng; Ding YaozhongONCOTARGET, 2016, 7(29): 45678-45686.
查看全部 →

发表信息

论文状态
公开发表
期刊
Oncology Research
发表日期
2022
卷期
第 30 卷, 第 2 期
页码
77-87
DOI
10.32604/or.2022.026511
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773167]; Project of Traditional Chinese Medicine of Guangdong Administration [20132155]; Medical and Health Science and Technology Project of Guangzhou Baiyun District [2020-YL-002]

作者

  • L

    LI, Xiaoyin (第一作者)

  • W

    Wang, Qian

    guangzhou univ chinese med

查看全部 7 位作者收起作者
  • L

    Liang, Hongfeng

    2 · guangdong prov hosp · guangzhou univ chinese med

  • C

    Chen, Shisheng

    southern med univ

  • C

    Chen, Haiwen

  • L

    Lu, Yaoyong (通讯)

  • Y

    Yang, Changfu (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417